Human Monoclonal Antibody Therapy

Human Monoclonal Antibody Therapy

Denosumab (Trade Name: Xgeva®)

Denosumab (XGEVA) is used for prostate cancer patients with metastatic bone disease to prevent fractures, severe bone pain and spinal cord compression. This treatment is given to patients in an ambulatory surgical center or a hospital. XGEVA contains denosumab, a protein (monoclonal antibody) that works to slow down bone destruction caused by cancer spreading to the bone (bone metastasis). XGEVA is used in adults with cancer to prevent serious complications caused by bone metastasis (e.g. fracture, pressure on the spinal cord or the need to receive radiation therapy or surgery). XGEVA is administered once every four weeks, as a single injection under the skin (subcutaneous).

 

Denosumab (Trade Name: Prolia®)

Denosumab (Prolia) is used to increase bone mass in men with non-metastatic prostate cancer who are receiving hormonal therapy and are at high risk for fracture.  This treatment is given to patients in an ambulatory surgical center or a hospital. Prolia contains denosumab, a protein (monoclonal antibody) that works to reduce the incidence of vertebral fractures. Prolia is administered once every six months, as a single injection under the skin (subcutaneous).